Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.

Aim: Curative treatment of thyroid cancer is a major issue for patients with end stage renal disease (ESRD) undergoing dialysis because they might not be included in a renal transplant protocol once they have overcome this disease. Since 131I is mostly eliminated by the kidneys, there is concern regarding the toxicity, efficacy and feasibility of 131I-therapy of anuric dialyzed patients.

Methods: This paper reports on 131I uptake and elimination from remnant thyroid tissue (T), salivary glands (SG), stomach (S) and blood, after administration of 3.

Immunoradiometric assay of thyroglobulin in patients with differentiated thyroid carcinomas: need for thyroglobulin recovery tests.

As interference from thyroglobulin autoantibodies appears to have been overcome in new commercial thyroglobulin assays by the use of monoclonal antibodies, the need for thyroglobulin recovery tests became uncertain. Sera (n=45) from patients with differentiated thyroid carcinomas were selected on the basis of a thyroglobulin recovery value below 70% in the Dynotest Tg immunoradiometric assay (Brahms) routinely used in our laboratory. Serum thyroglobulin levels were then measured using three other commercial immunoradiometric assays: thyroglobulin ERIA (Pasteur), HTGK (Sorin) and ELSA HTG (Cis Bio International).

First selective amygdalohippocampal radiosurgery for 'mesial temporal lobe epilepsy'.

All the well-documented radiosurgery of epilepsy cases are secondary epilepsies with space-occupying lesions. These results have prompted the idea of testing radiosurgery as a new way of treating epilepsy without space-occupying lesions. We have treated 4 patients with 'mesial temporal lobe epilepsy'.

Effect of drug transit time between exchange locus with plasma and sampling site.

In pharmacokinetic models used to describe the behavior of drugs in living organisms, generally neither the amount of drug flowing in pipes between compartments nor the transfer delay between the plasma-lymph exchange areas and a site of measurement are taken into account. Several former publications dealt with exchanges between two or more different organs assuming that the blood flow was constant or that the variation of the lymphatic flow was negligible or noting that the amount of drug present in pipes was not easily taken into account. In this article, we deal with concentration in a site of interstitial exchanges with regard to concentration in a sampling site with a varying blood flow, assuming that the transit time depends both on the fluid flow and the path length through pipes.